Increased paired box transcription factor 8 has a survival function in Glioma

BMC Cancer

Noelyn Hung⁷  Yu-Jen Chen⁷  Ahmad Taha⁵  Magnus Olivecrona⁶  Ronald Boet¹  Anna Wiles⁴  Tracy Warr⁸  Alisha Shaw⁷  Ramona Eiholzer⁷  Bruce C Baguley²  Michael R Eccles⁷  Antony W Braithwaite³  Martin MacFarlane¹  Janice A Royds⁷  Tania Slatter⁷ 

[1] Christchurch Hospital, Christchurch, New Zealand

[2] Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand

[3] Children’s medical research Institute, University of Sydney, Westmead, Australia

[4] Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

[5] Dunedin Public Hospital, Dunedin, New Zealand

[6] Department of Pharmacology and Clinical Neuroscience, Neurosurgery, Umea University, Umea, Sweden

[7] Department of Pathology, University of Otago, Dunedin, New Zealand

[8] Department of Molecular Neuroscience, Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK

关键词: Cell survival;    BCL2;    ALT;    Telomerase;    Telomere maintenance mechanism;    Glioma;    Glioblastoma;    PAX8;   

Others  :  858997
DOI  :  10.1186/1471-2407-14-159

 received in 2013-09-18, accepted in 2014-02-28,  发布年份 2014

【 摘 要 】

Background

The molecular basis to overcome therapeutic resistance to treat glioblastoma remains unclear. The anti-apoptotic b cell lymphoma 2 (BCL2) gene is associated with treatment resistance, and is transactivated by the paired box transcription factor 8 (PAX8). In earlier studies, we demonstrated that increased PAX8 expression in glioma cell lines was associated with the expression of telomerase. In this current study, we more extensively explored a role for PAX8 in gliomagenesis.

Methods

PAX8 expression was measured in 156 gliomas including telomerase-negative tumours, those with the alternative lengthening of telomeres (ALT) mechanism or with a non-defined telomere maintenance mechanism (NDTMM), using immunohistochemistry and quantitative PCR. We also tested the affect of PAX8 knockdown using siRNA in cell lines on cell survival and BCL2 expression.

Results

Seventy-two percent of glioblastomas were PAX8-positive (80% telomerase, 73% NDTMM, and 44% ALT). The majority of the low-grade gliomas and normal brain cells were PAX8-negative. The suppression of PAX8 was associated with a reduction in both cell growth and BCL2, suggesting that a reduction in PAX8 expression would sensitise tumours to cell death.

Conclusions

PAX8 is increased in the majority of glioblastomas and promoted cell survival. Because PAX8 is absent in normal brain tissue, it may be a promising therapeutic target pathway for treating aggressive gliomas.

【 授权许可】

   
2014 Hung et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Barnholtz-Sloan JS, Sloan AE, Schwartz AG: Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumours, 1973–1997. J Neurosurg 2003, 99:458-466.
• [2]Adamson DC, Rasheed BA, McLendon RE, Bigner DD: Central nervous system. Cancer Biomark 2010, 9:193-210.
• [3]Hakin-Smith V, Jellinek DA, Levy D, Carroll T, Teo M, Timperley WR, McKay MJ, Reddel RR, Royds JA: Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 2003, 361:836-838.
• [4]Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW: An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
• [5]Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
• [6]Robson EJ, He SJ, Eccles MR: A PANorama of PAX genes in cancer and development. Nat Rev Cancer 2006, 6:52-62.
• [7]Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, Fletcher JA: PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 2000, 289:1357-1360.
• [8]Silberstein GB, Dressler GR, Van Horn K: Expression of the PAX2 oncogene in human breast cancer and its role in progesterone-dependent mammary growth. Oncogene 2002, 21:1009-1016.
• [9]Wu H, Chen Y, Liang J, Shi B, Wu G, Zhang Y, Wang D, Li R, Yi X, Zhang H, Sun L, Shang Y: Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature 2005, 438:981-987.
• [10]Busslinger M, Klix N, Pfeffer P, Graninger PG, Kozmik Z: Deregulation of PAX-5 by translocation of the Emu enhancer of the IgH locus adjacent to two alternative PAX-5 promoters in a diffuse large-cell lymphoma. Proc Nat Acad Sci USA 1996, 93:6129-6134.
• [11]Doddrell RD, Dun XP, Moate RM, Jessen KR, Mirsky R, Parkinson DB: Regulation of Schwann cell differentiation and proliferation by the Pax-3 transcription factor. Glia 2012, 60:1269-1278.
• [12]Stuart ET, Haffner R, Oren M, Gruss P: Loss of p53 function through PAX-mediated transcriptional repression. EMBO J 1995, 14:5638-5645.
• [13]Macchia PE, Lapi P, Krude H, Pirro MT, Missero C, Chiovato L, Souabni A, Baserga M, Tassi V, Pinchera A, Fenzi G, Gruters A, Busslinger M, Di Lauro R: PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis. Nat Genet 1998, 19:83-86.
• [14]Muratovska A, Zhou C, He S, Goodyer P, Eccles MR: Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene 2003, 22:7989-7997.
• [15]Bernasconi M, Remppis A, Fredericks WJ, Rauscher FJ 3rd, Schafer BW: Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Nat Acad Sci USA 1996, 93:13164-13169.
• [16]Stoykova A, Gruss P: Roles of Pax-genes in developing and adult brain as suggested by expression patterns. J Neurosci 1994, 14:1395-1412.
• [17]Chen YJ, Campbell HG, Wiles AK, Eccles MR, Reddel RR, Braithwaite AW, Royds JA: PAX8 regulates telomerase reverse transcriptase and telomerase RNA component in glioma. Cancer Res 2008, 68:5724-5732.
• [18]Maulbecker CC, Gruss P: The oncogenic potential of Pax genes. EMBO J 1993, 12:2361-2367.
• [19]Li CG, Nyman JE, Braithwaite AW, Eccles MR: PAX8 promotes tumours cell growth by transcriptionally regulating E2F1 and stabilizing RB protein. Oncogene 2011, 30:4824-4834.
• [20]Oji Y, Suzuki T, Nakano Y, Maruno M, Nakatsuka S, Jomgeow T, Abeno S, Tatsumi N, Yokota A, Aoyagi S, Nakazawa T, Ito K, Kanato K, Shirakata T, Nishida S, Hosen N, Kawakami M, Tsuboi A, Oka Y, Aozasa K, Yoshimine T, Sugiyama H: Overexpression of the Wilms’ tumours gene W T1 in primary astrocytic tumours. Cancer Sci 2004, 95:822-827.
• [21]Strik H, Deininger M, Streffer J, Grote E, Wickboldt J, Dichgans J, Weller M, Meyermann R: BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy. J Neurol Neurosurg Psychiatry 1999, 67:763-768.
• [22]Rieger L, Weller M, Bornemann A, Schabet M, Dichgans J, Meyermann R: BCL-2 family protein expression in human malignant glioma: a clinical-pathological correlative study. J Neurol Sci 1998, 155:68-75.
• [23]Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A: Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 1995, 95:2633-2643.
• [24]Doucette T, Yang Y, Zhang W, Fuller GN, Suki D, Fults DW, Rao G: Bcl-2 promotes malignant progression in a PDGF-B-dependent murine model of oligodendroglioma. Int J Cancer 2011, 129:2093-2103.
• [25]Wick W, Wagner S, Kerkau S, Dichgans J, Tonn JC, Weller M: BCL-2 promotes migration and invasiveness of human glioma cells. FEBS Letters 1998, 440:419-424.
• [26]Royds JA, Al Nadaf S, Wiles AK, Chen YJ, Ahn A, Shaw A, Bowie S, Lam F, Baguley BC, Braithwaite AW, MacFarlane MR, Hung NA, Slatter TL: The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival. PLoS One 2011, 6:e26737.
• [27]Slatter T, Gifford-Garner J, Wiles A, Tan X, Chen YJ, MacFarlane M, Sullivan M, Royds J, Hung N: Pilocytic astrocytomas have telomere-associated promyelocytic leukemia bodies without alternatively lengthened telomeres. Am J Pathol 2010, 177:2694-2700.
• [28]Kozmik Z, Kurzbauer R, Dorfler P, Busslinger M: Alternative splicing of Pax-8 gene transcripts is developmentally regulated and generates isoforms with different transactivation properties. Mol Cell Biol 1993, 13:6024-6035.
• [29]Fraizer GC, Shimamura R, Zhang X, Saunders GF: PAX 8 regulates human WT1 transcription through a novel DNA binding site. J Biol Chem 1997, 272:30678-30687.
• [30]Ui-Tei K, Naito Y, Takahashi F, Haraguchi T, Ohki-Hamazaki H, Juni A, Ueda R, Saigo K: Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res 2004, 32:936-948.
• [31]Hewitt SM, Hamada S, Monarres A, Kottical LV, Saunders GF, McDonnell TJ: Transcriptional activation of the bcl-2 apoptosis suppressor gene by the paired box transcription factor PAX8. Anticancer Res 1997, 17:3211-3215.
• [32]Park D, Jia H, Rajakumar V, Chamberlin HM: Pax2/5/8 proteins promote cell survival in C. elegans. Development 2006, 133:4193-4202.
• [33]Tacha D, Zhou D, Cheng L: Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol 2011, 19:293-299.
• [34]Shapiro DN, Sublett JE, Li B, Downing JR, Naeve CW: Fusion of PAX3 to a member of the forkhead family of transcription factors in human aleveolar rhabdomyosarcoma. Cancer Res 1993, 53:5108-5112.
• [35]Sublett JE, Jeon IS, Shapiro DN: The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator. Oncogene 1995, 11:545-552.
• [36]Au AY, McBride C, Wilhelm KG Jr, Koenig RJ, Speller B, Cheung L, Messina M, Wentworth J, Tasevski V, Learoyd D, Robinson BG, Clifton-Bligh RJ: PAX8-peroxisome proliferator-activated receptor gamma (PPARgamma) disrupts normal PAX8 or PPARgamma transcriptional function and stimulates follicular thyroid cell growth. Endocrinology 2006, 147:367-376.
• [37]Eberhardt NL, Grebe SK, McIver B, Reddi HV: The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol Cell Endocrinol 2010, 321:50-56.
• [38]Gregory Powell J, Wang X, Allard BL, Sahin M, Wang XL, Hay ID, Hiddinga HJ, Deshpande SS, Kroll TG, Grebe SK, Eberhardt NL, McIver B: The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition. Oncogene 2004, 23:3634-3641.
• [39]Li CG, Eccles MR: PAX Genes in Cancer; Friends or Foes? Front Genet 2012, 3:6.
• [40]Bhat KP, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F, James JD, Gumin J, Diefes KL, Kim SH, Turski A, Azodi Y, Yang Y, Doucette T, Colman H, Sulman EP, Lang FF, Rao G, Copray S, Vaillant BD, Aldape KD: The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev 2011, 25:2594-2609.
• [41]Di Palma T, D’Andrea B, Liguori GL, Liguoro A, de Cristofaro T, Del Prete D, Pappalardo A, Mascia A, Zannini M: TAZ is a coactivator for Pax8 and TTF-1, two transcription factors involved in thyroid differentiation. Exp Cell Res 2009, 315:162-175.
• [42]Buttiglieri S, Deregibus MC, Bravo S, Cassoni P, Chiarle R, Bussolati B, Camussi G: Role of Pax2 in apoptosis resistance and proinvasive phenotype of Kaposi’s sarcoma cells. J Biol Chem 2004, 279:4136-4143.
• [43]Jiang Z, Zheng X, Rich KM: Down-regulation of Bcl-2 and Bc1-xL expression with bispecific antisense treatment in giloblastoma cell lines induce cell death. J Neurochem 2003, 84:273-281.
• [44]Julien T, Frankel B, Longo S, Kyle M, Gibson S, Shillitoe E, Ryken T: Antisense-mediated inhibition of the bcl-2 gene induces apoptosis in human malignant glioma. Surg Neurol 2000, 53:360-368. discussion 368–9
• [45]Di Palma T, Conti A, de Cristofaro T, Scala S, Nitsch L, Zannini M: Identification of novel Pax8 targets in FRTL-5 thyroid cells by gene silencing and expression microarray analysis. PLoS one 2011, 6:e25162.